Medical robotics company Myomo Inc announces it has obtained a CE Mark approving the commercialization of its MyoPro myoelectric arm orthosis across the European Economic Area (EEA).
“The MyoPro powered brace allows individuals suffering from paralysis or stroke to perform routine daily activities,” says Paul R. Gudonis, chairman and CEO of Myomo, in a media release. “Gaining CE Mark approval is an important milestone for our company and for the many people in Europe who will now be able to experience the benefits of MyoPro as they struggle with upper limb paralysis.”
“We are currently working with our partner Ottobock to plan our European launch beginning in Germany,” Gudonis continues. “Myomo recently conducted sales and clinical training for Ottobock staff, which has begun evaluating patients for the MyoPro device.”
Myomo launched its next-generation MyoPro orthosis in June 2017. Three models are available to match the needs of each patient, the release continues.
[Source(s): Myomo Inc, Business Wire]
